Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France
Samira Fafi‐Kremer(Centre National de la Recherche Scientifique), Arnaud Fontanet(Institut Pasteur), de Sèze(Hôpital d'Hautepierre), Aurélie Velay(Hôpitaux Universitaires de Strasbourg), Timothée Bruel(Institut Pasteur), Pierre Charneau(Institut Pasteur), Catherine Schmidt‐Mutter(Inserm), Isabelle Staropoli(Centre National de la Recherche Scientifique), Rebecca Grant(University Hospital of Geneva), Olivier Schwartz(Centre National de la Recherche Scientifique), Yoann Madec(Institut Pasteur), Alexandre Bolle(Inserm), Ludivine Grzelak(The University of Melbourne), Philippe Souque(Centre National de la Recherche Scientifique), Nicolas Collongues(Inserm), Laura Tondeur(Institut Pasteur), Marie Mielcarek, David Rey, Nicolás Meyer, Bruno Hoen(Inserm), Nicolas Lefèbvre(Hôpital Civil, Strasbourg), François Anna(Institut Pasteur)
Cited by 36
Related Papers
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
|Neurology|2015|4.6k
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
|New England Journal of Medicine|2016|1.9k
Blood‐brain barrier‐specific properties of a human adult brain endothelial cell line
|The FASEB Journal|2005|1.3k
MOG encephalomyelitis: international recommendations on diagnosis and antibody testing
|Journal of Neuroinflammation|2018|740
Ofatumumab versus Teriflunomide in Multiple Sclerosis
|New England Journal of Medicine|2020|706